Generic Somatostatin Analogues for Neuroendocrine Cancer

Generic Somatostatin Analogues for Neuroendocrine Cancer

Treatment
Updated 18th December 2021 News just in..... the first generic version of Somatuline Depot (Lanreotide) in the US has been approved for marketing by the US FDA according to a press release from the company Cipla. This can often lead to price reductions, but I have no details other than what I published in my generic somatostatin analogues blog post attached. The active ingredient, route of administration and strengths are the same as SOMATULINE DEPOT®, from Ipsen Biopharmaceuticals Inc.  See the Lanreotide section below. I've covered a lot about somatostatin analogues, particularly the two predominant approved drugs Lanreotide and Octreotide.  Recently I read about generic drugs and found there are some for octreotide and as at Jul 2021, at least one for Lanreotide.  I was concerned to hear a patient asking a…
Read More